Clinical Pharmacokinetics

, Volume 30, Issue 1, pp 52–76 | Cite as

Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines

  • Bart E. Laurijssens
  • David J. Greenblatt
Review Article Pharmacokinetic-Pharmacodynamic Relationships

Summary

This article reviews the literature on the plasma concentration-effect relationships for benzodiazepines, in humans and in experimental animals. Only literature that explicitly links pharmacokinetics to pharmacodynamics is included. The following questions are evaluated.

  • Can concentration-effect relationships be demonstrated?

  • If so, are these relations stable?

  • Are the influences of specific factors such as age and disease on these relationships established?

It is clear that, when studies are conducted and interpreted appropriately, relations can be found for a wide range of benzodiazepine effects. These include objective measures such as electroencephalography, semisubjective measures such as psychomotor performance, and subjective measures such as mood/sedation scales. A generally applicable model of the relationship which will allow prediction of effect is, however, not yet established. The relationship appears to be dependent on route and rate of administration, because of factors such as distributional delay, formation of active metabolites and, probably, acute tolerance. Furthermore, intra- and interindividual variability is considerable, probably due to varying experimental conditions and intrinsic interindividual differences.

The limited data available on factors influencing the plasma concentration-effect relationships for benzodiazepines demonstrate clear changes in the pharmacodynamics after multiple doses, suggesting the development of tolerance, and a subsensitivity in patients with panic disorder. The influence of factors such as age, disease and drug interactions on the pharmacokinetic-pharmacodynamic relationship remains less clear.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44: 151–347PubMedGoogle Scholar
  2. 2.
    Hollister LE, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13 (Dec Suppl.): 1S–169SPubMedGoogle Scholar
  3. 3.
    Greenblatt DJ, Friedman HL, Shader RI. Correlating pharmacokinetics and pharmacodynamics of benzodiazepines: problems and assumptions. In: Dahl SG, Gram LF, Paul SM, et al., editors. Clinical pharmacology in psychiatry. Selectivity in psychotropic drug action — promises or problems. Berlin/Heidelberg: Springer-Verlag, 1987: 62–71Google Scholar
  4. 4.
    Grevel J. Kinetic-effect models and their applications. Pharm Res 1987; 4: 86–91PubMedGoogle Scholar
  5. 5.
    Greenblatt DJ, Harmatz JS. Kinetic-dynamic modeling in clinical psychopharmacology. J Clin Psychopharmacol 1993; 13: 231–4PubMedGoogle Scholar
  6. 6.
    Campbell DB. The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology 1990; 100: 433–50PubMedGoogle Scholar
  7. 7.
    Dingemanse J, Danhof M, Breimer DD. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther 1988; 38: 1–52PubMedGoogle Scholar
  8. 8.
    Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 1992; 23: 191–215PubMedGoogle Scholar
  9. 9.
    Greenblatt DJ. Principles of pharmacokinetics and pharmacodynamics. In: Nemeroff CB, Schatzberg AF, editors. The American Psychiatric Press Textbook of Psychopharmacology. Washington (DC): American Psychiatric Press, 1995: 125–36Google Scholar
  10. 10.
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (Part II). Clin Pharmacokinet 1991; 21: 262–73PubMedGoogle Scholar
  11. 11.
    Hommer DW, Matsuo VM, Wolkowitz O, et al. Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry 1986; 43: 542–51PubMedGoogle Scholar
  12. 12.
    Roy-Byrne PP, Lewis N, Villacres E, et al. Suppression of norepinephrine appearance rate in plasma by diazepam in humans. Life Sci 1988; 43: 1615–23PubMedGoogle Scholar
  13. 13.
    Breimer LTM, Burm AGL, Danhof M, et al. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991; 20: 497–508PubMedGoogle Scholar
  14. 14.
    Greenblatt DJ, Harmatz JS, Gouthro TA, et al. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994; 56: 100–11PubMedGoogle Scholar
  15. 15.
    Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691–8PubMedGoogle Scholar
  16. 16.
    Kaiser L. Adjusting for baseline: change or percentage change. Stat Med 1989; 8: 1183–90PubMedGoogle Scholar
  17. 17.
    Wainer H. Adjusting for differential base rates: Lord’s paradox again. Psychol Bull 1991; 109: 147–51PubMedGoogle Scholar
  18. 18.
    Crevoisier C, Ziegler WH, Eckert M, et al. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983; 16: 51S–61SPubMedGoogle Scholar
  19. 19.
    Ellinwood EH, Nikaido AM, Gupta SK, et al. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J Psychopharmacol 1993; 7: 24–32PubMedGoogle Scholar
  20. 20.
    Koopmans R, Dingemanse J, Danhof M, et al. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. Clin Pharmacol Ther 1991; 50: 16–24PubMedGoogle Scholar
  21. 21.
    Kroboth PD, Bertz RJ, Smith RB. Acute tolerance to triazolam during continuous and step infusions: estimation of the effect offset rate constant. J Pharmacol Exp Ther 1993; 264: 1047–55PubMedGoogle Scholar
  22. 22.
    Holford NHG, Sheiner LB. Kinetics of pharmacological response. Pharmacol Ther 1982; 16: 143–66PubMedGoogle Scholar
  23. 23.
    Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 1981; 9: 367–88PubMedGoogle Scholar
  24. 24.
    Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358–71PubMedGoogle Scholar
  25. 25.
    Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733–41PubMedGoogle Scholar
  26. 26.
    Veng-Pedersen P, Mandema JW, Danhof M. A system approach to pharmacodynamics, III: an algorithm and computer program ‘COLAPS’ for pharmacodynamic modelling. J Pharm Sci 1991; 80: 488–95PubMedGoogle Scholar
  27. 27.
    Verotta D, Beal SL, Sheiner LB. Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am J Physiol 1984; 256: R1005–10Google Scholar
  28. 28.
    Ekblom M, Hammarlund-Udenaes M, Paalzow L. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats. J Pharmacol Exp Ther 1993; 266: 244–52PubMedGoogle Scholar
  29. 29.
    Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988; 244: 231–6PubMedGoogle Scholar
  30. 30.
    Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 19: 521–36Google Scholar
  31. 31.
    Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406–19PubMedGoogle Scholar
  32. 32.
    Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 1994; 56: 356–8PubMedGoogle Scholar
  33. 33.
    Smith RB, Kroboth PD, Varner PD. Pharmacodynamics of triazolam after intravenous administration. J Clin Pharmacol 1987; 27: 971–9PubMedGoogle Scholar
  34. 34.
    Sunzel M, Paalzow L, Berggren L, et al. Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol 1988; 25: 561–9PubMedGoogle Scholar
  35. 35.
    Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356–65PubMedGoogle Scholar
  36. 36.
    Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Kinetic and dynamic study of intravenous lorazepam: comparisom with intravenous diazepam. J Pharmacol Exp Ther 1989; 250: 134–40PubMedGoogle Scholar
  37. 37.
    Breimer LTM, Hennis PJ, Burm AGL, et al. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers: pharmacokinetic/pharmacodynamic modelling. Clin Pharmacokinet 1990; 18: 245–53PubMedGoogle Scholar
  38. 38.
    Bührer M, Maitre PO, Crevoisier C, et al. Electroencephalographic effects of benzodiazepines. II: Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990; 48: 555–67PubMedGoogle Scholar
  39. 39.
    Fleishaker JC, Smith TC, Friedman H. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in healthy volunteers. Eur J Clin Pharmacol 1992; 42: 287–94PubMedGoogle Scholar
  40. 40.
    Derry CL, Kroboth PD, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J Clin Psychopharmacol 1995; 15: 197–205PubMedGoogle Scholar
  41. 41.
    Mould DR, DeFeo TM, Reele S, et al. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clin Pharmacol Ther 1995; 58: 35–43PubMedGoogle Scholar
  42. 42.
    Persson MP, Nilsson A, Hartvig P. Relation of sedation and amnesia to plasma concentrations of midazolam in surgical patients. Clin Pharmacol Ther 1988; 43: 324–31PubMedGoogle Scholar
  43. 43.
    Osman OT, DeVane CL, Greenblatt DJ, et al. Pharmacokinetic and dynamic correlates of intravenus alprazolam challenge. Clin Pharmacol Ther 1991; 50: 656–62PubMedGoogle Scholar
  44. 44.
    Short TG, Young KK, Tan P, et al. Midazolam and flumazenil pharmacokinetics and pharmacodynamics following simultaneous administration to human volunteers. Acta Anaesthesiol Scand 1994; 38: 350–6PubMedGoogle Scholar
  45. 45.
    Fink M, Irwin P, Weinfeld RE, et al. Blood levels and electroencephalographic effects of diazepam and bromazepam. Clin Pharmacol Ther 1976; 20: 184–91PubMedGoogle Scholar
  46. 46.
    MacLeod SM, Giles HG, Patzalek G, et al. Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol 1977; 11: 345–9PubMedGoogle Scholar
  47. 47.
    Bittencourt PRM, Wade P, Smith AT, et al. The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration. Br J Clin Pharmacol 1981; 12: 523–33PubMedGoogle Scholar
  48. 48.
    Ellinwood EH, Linnoila M, Easier ME, et al. Profile of acute tolerance to three sedative anxiolytics. Psychopharmacology 1983; 79: 137–41PubMedGoogle Scholar
  49. 49.
    Baktir G, Fisch HU, Huguenin P, et al. Triazolam concentration-effect relationships in healthy subjects. Clin Pharmacol Ther 1983; 34: 195–201PubMedGoogle Scholar
  50. 50.
    Ellinwood EH, Easier ME, Linnoila M, et al. Effects of oral contraceptives on diazepam-induced psychomotor impairment. Clin Pharmacol Ther 1984; 35: 360–6PubMedGoogle Scholar
  51. 51.
    O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18: 121S–129SPubMedGoogle Scholar
  52. 52.
    Stevens LA, Pidgen AW, Bevan CD, et al. Correlation of the clinical pharmacodynamics of loprazolam with serum concentration. Xenobiotica 1985; 15: 623–31PubMedGoogle Scholar
  53. 53.
    Ellinwood EH, Heatherly DG, Nikaido AM, et al. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985; 86: 392–9PubMedGoogle Scholar
  54. 54.
    Ellinwood EH, Nikaido AM, Heatherly DG, et al. Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms. Psychopharmacology 1987; 91: 168–74PubMedGoogle Scholar
  55. 55.
    Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 1987; 93: 105–12PubMedGoogle Scholar
  56. 56.
    Koopmans R, Dingemanse J, Danhof M, et al. Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther 1988; 44: 14–22PubMedGoogle Scholar
  57. 57.
    Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 1989; 99: 34–9PubMedGoogle Scholar
  58. 58.
    Greenblatt DJ, Harmatz JS, Engelhardt N, et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch Gen Psychiatry 1989; 46: 326–32PubMedGoogle Scholar
  59. 59.
    Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines, II: Triazolam. Pharm Res 1990; 7: 570–6PubMedGoogle Scholar
  60. 60.
    Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. J Pharmacokinet Biopharm 1990; 18: 89–102PubMedGoogle Scholar
  61. 61.
    Kroboth PD, McAuley JW, Smith RB. Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 1990; 100: 477–84PubMedGoogle Scholar
  62. 62.
    Fleishaker JC, Smith TC, Friedman H, et al. N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10–50 mg oral doses in healthy volunteers. Psychopharmacology 1991; 105: 181–5PubMedGoogle Scholar
  63. 63.
    Grahnén S, Wennerlund B, Dahlström B, et al. Inter-and intra-individual variability in the concentration-effect (sedation) relationship of flunitrazepam. Br J Clin Pharmacol 1991; 31: 89–92PubMedGoogle Scholar
  64. 64.
    Schmith VD, Piraino B, Smith RB, et al. Alprazolam in end-stage renal disease. II: Pharmacodynamics. Clin Pharmacol Ther 1992; 51: 533–40PubMedGoogle Scholar
  65. 65.
    Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52: 139–50PubMedGoogle Scholar
  66. 66.
    van Steveninck AL, Schoemaker HC, Pieters MSM, et al. A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50: 172–80PubMedGoogle Scholar
  67. 67.
    van Steveninck AL, Verver S, Schoemaker HC, et al. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers. Clin Pharmacol Ther 1992; 52: 402–8PubMedGoogle Scholar
  68. 68.
    Osborne GA, Badcock NR, McGrath PM, et al. The relationship between the concentration of temazepam in cerebrospinal fluid and sedation in man. Anaesthesia 1992; 47: 303–6PubMedGoogle Scholar
  69. 69.
    Greenblatt DJ, Scavone JM, Harmatz JS, et al. Cognitive effects of β-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propanolol, atenolol, lorazepam, and placebo. Clin Pharmacol Ther 1993; 53: 577–84PubMedGoogle Scholar
  70. 70.
    Golden PL, Warner PE, Fleishaker JC, et al. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. Clin Pharmacol Ther 1994; 56: 133–41PubMedGoogle Scholar
  71. 71.
    McAuley JW, Reynolds IJ, Kroboth FJ, et al. Orally administered progesterone enhances sensitivity to triazolam in postmenopausal woman. J Clin Psychopharmacol 1995; 15: 3–11PubMedGoogle Scholar
  72. 72.
    Moffat AC, Osborne GA, Badcock NR, et al. The relationship between clinical effect and concentrations of temazepam in plasma and cerebrospinal fluid. Anaesthesia 1995; 50: 3–8PubMedGoogle Scholar
  73. 73.
    von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. In press, 1995Google Scholar
  74. 74.
    Miller LG, Greenblatt DJ, Paul SM, et al. Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 1987; 240: 516–22PubMedGoogle Scholar
  75. 75.
    Greenblatt DJ, Sethy VH. Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology 1990; 102: 373–8PubMedGoogle Scholar
  76. 76.
    Mandema JW, Sansom LN, Dios-Vieitez MC, et al. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 1991; 257: 472–8PubMedGoogle Scholar
  77. 77.
    Mandema JW, Kuck MT, Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol 1992; 105: 164–70PubMedGoogle Scholar
  78. 78.
    Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 1992; 260: 36–44PubMedGoogle Scholar
  79. 79.
    Mandema JW, Kuck MT, Danhof M. In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J Pharmacol Exp Ther 1992; 261: 56–61PubMedGoogle Scholar
  80. 80.
    Dingemanse J, Sollie FAE, Breimer DD, et al. Pharmacokinetic modelling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazole threshold concentration as pharmacodynamic measure. J Pharmacokinet Biopharm 1988; 16: 203–28PubMedGoogle Scholar
  81. 81.
    Hollander-Jansen M, Dingemanse J, Langemeijer MWE, et al. Relation between receptor occupancy and anticonvulsant effect of flunitrazepam in rats. Pharm Res 1989; 6: 585–91PubMedGoogle Scholar
  82. 82.
    Dingemanse J, Voskuyl RA, Langemeijer MWE, et al. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. Br J Pharmacol 1990; 99: 53–8PubMedGoogle Scholar
  83. 83.
    Hoogerkamp A, Vis PW, Danhof M, et al. Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. J Pharmacol Exp Ther 1994; 269: 521–8PubMedGoogle Scholar
  84. 84.
    Hall RI, Szlam F, Hug CC. Pharmacokinetics and pharmacodynamics of midazolam in the enflurane-anesthetized dog. J Pharmacokinet Biopharm 1988; 16: 251–62PubMedGoogle Scholar
  85. 85.
    Court MH, Dodman NH, Greenblatt DJ, et al. Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthesized with halothane. Anesthesiology 1993; 78: 155–62PubMedGoogle Scholar
  86. 86.
    Bond AJ, Hailey DM, Lader MH. Plasma concentrations of benzodiazepines. Br J Clin Pharmacol 1977; 4: 51–6PubMedGoogle Scholar
  87. 87.
    Dasberg HH, van der Kleijn E, Guelen PJR, et al. Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin Pharmacol Ther 1973; 15: 473–83Google Scholar
  88. 88.
    Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 715–22PubMedGoogle Scholar
  89. 89.
    Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: preliminary results. J Clin Psychopharmacol 1991; 11: 48–51PubMedGoogle Scholar
  90. 90.
    Ciraulo DA, Barnhill JG, Boxenbaum HG, et al. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. J Clin Pharmacol 1986; 26: 292–8PubMedGoogle Scholar
  91. 91.
    Ciraulo DA, Antal EJ, Smith RB, et al. The relation of alprazolam dose to steady-state plasma concentrations. J Clin Psychopharmacol 1990; 10: 27–32PubMedGoogle Scholar
  92. 92.
    Lesser IM, Lydiard B, Antal E, et al. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992; 149: 1556–62PubMedGoogle Scholar
  93. 93.
    Fleishaker JC, Phillips JP, Eller MG, et al. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation. J Clin Pharmacol 1989; 29: 543–9PubMedGoogle Scholar
  94. 94.
    Smith RB, Kroboth PD, Vanderlugt JT, et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984; 84: 452–6PubMedGoogle Scholar
  95. 95.
    Kroboth PD, Smith RB. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharmacol Ther 1988; 43: 270–7PubMedGoogle Scholar
  96. 96.
    Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715–28PubMedGoogle Scholar
  97. 97.
    Mandema JW, Tukker E, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 1991; 102: 663–8PubMedGoogle Scholar
  98. 98.
    Kroboth PD, McAuley JW, Derry CL. Time-dependent sensitization to triazolam? An observation in three studies. J Clin Psychopharmacol 1995; 15: 192–6PubMedGoogle Scholar
  99. 99.
    Stijnen AM. The influence of ageing on the pharmacodynamics of sedative anticonvulsant drugs in rats [Ph.D. thesis]. Leiden: University of Leiden, 1991Google Scholar
  100. 100.
    Scavone JM, Friedman H, Greenblatt DJ, et al. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arztneim Forsch 1987; 37: 2–6Google Scholar
  101. 101.
    Barnhill JG, Greenblatt DJ, Miller LG, et al. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther 1990; 253: 1153–61PubMedGoogle Scholar
  102. 102.
    Hovinga S, Stijnen AM, Langemeijer MWE, et al. Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats. Br J Pharmacol 1992; 107: 171–7PubMedGoogle Scholar
  103. 103.
    Jacobs JR, Reves JG, White WD, et al. Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam. Anesthesiol Analg 1995; 80: 143–8Google Scholar
  104. 104.
    Roy-Byrne PP, Lewis N, Villacres E, et al. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry 1989; 26: 744–8PubMedGoogle Scholar
  105. 105.
    Roy-Byrne PP, Cowley DS, Greenblatt DJ, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47: 534–8PubMedGoogle Scholar
  106. 106.
    Ochs HR, Greenblatt DJ, Eckardt B, et al. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 1983; 33: 471–6PubMedGoogle Scholar
  107. 107.
    Robin DW, Lee M, Hasan SS, et al. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 630–7PubMedGoogle Scholar
  108. 108.
    Bakti G, Fisch HU, Karlaganis G, et al. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987; 7: 629–38PubMedGoogle Scholar
  109. 109.
    Schmith VD, Piraino B, Smith RB, et al. Alprazolam in end-stage renal disease. I: Pharmacokinetics. J Clin Pharmacol 1991; 31: 571–9PubMedGoogle Scholar
  110. 110.
    Hoyo-Vadillo C, Mandema JW, Danhof M. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. Life Sci 1995; 57: 325–33PubMedGoogle Scholar
  111. 111.
    Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93–141PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Bart E. Laurijssens
    • 1
  • David J. Greenblatt
    • 1
    • 2
  1. 1.Department of Pharmacology and Experimental TherapeuticsTufts University School of MedicineBostonUSA
  2. 2.Division of Clinical PharmacologyNew England Medical Center HospitalBostonUSA

Personalised recommendations